340B Drug Pricing Program
A statement on the 340B court decision from the AHA, AAMC and America鈥檚 Essential Hospitals
AHA expresses concern regarding recent action taken by three major drug manufacturers 鈥 Eli Lilly and Co., Merck and Sanofi 鈥 to limit the distribution of certain 340B drugs to our hospital members.
A panel of 4 experts discussed federal policy emerging from Congress and the Administration under COVID-19 focusing on rural health priorities and took questions from the audience. They reviewed emergency funding, Medicare and Medicaid payment improvements, telehealth, regulatory relief, 340B drug鈥
The AHA urged the Department of Health and Human Services and the Health Resources and Services Administration to provide flexibility in the administration of the 340B Drug Pricing Program to better enable these hospitals to serve their communities during the COVID-19 national emergency.
The AHA submitted its comments to the Office of Management and Budget regarding the Centers for Medicare & Medicaid Services (CMS) plans to collect pricing data on Hospital Survey for Specified Covered Outpatient Drugs (SCODs) from all hospitals that participate in the 340B Drug Pricing Program鈥
Model comment letter regarding CMS鈥10709, Hospital Survey for Specified Covered Outpatient Drugs; Agency Information Collection Activities: Proposed Collection; Comment Request (Vol. 85, No. 26), February 7, 2020.
The Health Resources and Services Administration should increase its oversight of private nonprofit hospitals that participate in the 340B drug savings program to ensure they meet eligibility requirements, the Government Accountability Office said in a report released today.
The pharmaceutical industry鈥檚 latest 鈥渞eport鈥 is an obvious attempt to divert attention away from a problem of their own making: skyrocketing drug prices.
Re: CMS鈥10709, Hospital Survey for Specified Covered Outpatient Drugs; Agency Information Collection Activities: Proposed Collection; Comment Request (Vol. 84, No. 189), September 30, 2019.